Full-Time
Confirmed live in the last 24 hours
Develops and commercializes biopharmaceuticals
No salary listed
Mid
Company Historically Provides H1B Sponsorship
Edmonton, AB, Canada
Gilead Sciences is a biopharmaceutical company that develops and sells medicines for various serious health conditions, including HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular issues. The company focuses on extensive research and development to create new therapies, which are then approved by regulatory authorities before being marketed to healthcare providers, hospitals, and pharmacies. Gilead stands out from its competitors by investing heavily in R&D and forming strategic partnerships, such as with SAP Ariba, to improve its supply chain and manufacturing practices. The company's goal is to enhance health equity and access to care globally, working with communities to ensure that its medicines reach those in need.
Company Size
10,001+
Company Stage
IPO
Headquarters
Foster City, California
Founded
1987
Help us improve and share your feedback! Did you find this helpful?
Paid family time off and paid parental time off
Generous 401(k) contribution matching
Comprehensive medical plans that cover both physical and mental healthcare
Global Wellbeing Reimbursement
Time Off
Global Volunteer Day
Giving Together Program
Employee Support Programs
Flexible Work Options
This time it's Gilead coming to the table with a fresh $11 billion in hand to spend across its manufacturing and research centers in the U.S.
Gilead to invest $32 billion in U.S. manufacturing and R&D through 2030 and create more than 3,000 direct and indirect jobs by 2028
On April 29, the Department of Justice (DOJ) announced that California-based pharmaceutical giant Gilead Sciences agreed to pay $202 million to settle charges of violating the False Claims Act and Anti-Kickback Statute.
Amgen competes with other biotech giants like Gilead Sciences and Biogen.
Foster City-based HIV drug company Gilead Sciences is laying off nearly 150 people, and the job cuts are significant among senior members of the company's management.